MGNX vs. INVA, LQDA, CNTA, ABVX, ZNTL, SAVA, IMNM, OPK, TYRA, and BLTE
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Innoviva (INVA), Liquidia (LQDA), Centessa Pharmaceuticals (CNTA), ABIVAX Société Anonyme (ABVX), Zentalis Pharmaceuticals (ZNTL), Cassava Sciences (SAVA), Immunome (IMNM), OPKO Health (OPK), Tyra Biosciences (TYRA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical preparations" industry.
MacroGenics (NASDAQ:MGNX) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
Innoviva has a net margin of 57.89% compared to MacroGenics' net margin of -15.42%. Innoviva's return on equity of 30.37% beat MacroGenics' return on equity.
MacroGenics received 123 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 63.33% of users gave MacroGenics an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
In the previous week, MacroGenics had 2 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for MacroGenics and 5 mentions for Innoviva. Innoviva's average media sentiment score of 1.03 beat MacroGenics' score of 0.54 indicating that Innoviva is being referred to more favorably in the news media.
MacroGenics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
MacroGenics currently has a consensus price target of $18.00, suggesting a potential upside of 25.87%. Given MacroGenics' higher possible upside, equities research analysts plainly believe MacroGenics is more favorable than Innoviva.
96.9% of MacroGenics shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 11.3% of MacroGenics shares are held by insiders. Comparatively, 1.4% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Innoviva beats MacroGenics on 9 of the 17 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
